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Introduction 
and Guido van der Groen 
Objective: To study the spread of antibodies to V3 loop peptides of two chimpanzee 
lentiviruses and the divergent H I V - ~ A ~ T - ~ ~  isolate (group O) in human sera from 
different geographic regions, and to compare this with reactions to peptides from 
known Nopth American (subtype B) and Zaïrean (subtype D) strains. 
Methods: A total 2495 HIV-1 -antibody-positive sera from nine countries were tested 
by enzyme-linked immunosorbent assay for antibodies to the V3 loop of 1 O HIV/SIV 
isolates (including MN, SF2, HXB2, RF, MAL, ELI, Z6 and ANT-70 for HIV-1, and 
cpz-gab and cpz-ant for SIV). 
Results: In each country, the highest prevalences were observed against the MN 
peptide (58.8-91.7%). Seroreactivity to other peptides from subtype B were generally 
lower. Prevalences of antibodies to V3 peptides derived from Za’irean strains 
belonging to subtype D were generally lower than to subtype B. Relative high 
prevalences of sera reactive with the SIV,pz-g& V3 peptide were observed. The lowest 
rates were seen in Brazil (4.2%) and Belgium (25.7%). Among the African countries, 
the prevalence rates varied between 30.1 and 67.6%. Prevalence to the V3 loop 
derived from the SIV,pz-,,t strains was much lower. Prevalence of sera reactive to 
the ANT-70 V3 loop peptide was very low, and the highest rates were observed 
in Cameroon (10.2%), Niger (6%) and Gabon (4.6%). Only the sera reactive to the 
ANT-70 V 3  loop peptide from Cameroon and Gabon were confirmed on a specific 
HIVANTJO Western blot (i.e., presence of antibodies to the envelope protein gpl20). 
Conclusions: The extent to which different V3 peptide reactivity patterns reflect 
the circulation of different HIV-1 strains in a particular population is not yet clear. 
However, V3 peptide serology using the very specific V3 peptide of the HIVANT-~O is 
a good indicator of the very aberrant group O in a particular population. 
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sequence heterogeneity is distributed throughout the 
whole genome, most is located in the env gene-[4]. Most 
of the sequence variability found in gp120 is clustered 
in five hypervariable domains (Vl-V5) [5-71. The third 
variable region (V3) is a major target of vaccine research, 
because it contains an important neutralization site, and 
has been shown to bind and elicit isolate-specific neu- 
tralizing antibodies [&11]. This segment ofthe envelope 
One of the problems in thqJevelopment of an effec- 
tive vaccine for AIDS is the genetic diversity of HIV-1. 
Numerous variant strains have been obtained &om dif- 
ferent geographic regions. At present, the HIV-1 virus 
group consist of five to eight genetic subtypes, depend- 
- ing on the coding sequence used [l-31. Although this 
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contains also B- and T-cell epitopes and plays a role 
in diverse functions such as infectivity, viral fusion and 
syncytium formation [12,13]. 
To develop a vaccine that is widely applicable, one must 
consider HIV-1 env gene variation. The principal ap- 
proach to monitor diversity has been through genetic se- 
quences, however, sequencing is expensive and laborious 
and therefore its use is limited. An alternative approach is 
serotyping which can be used to screen large population 
groups. Previous studies [14-161 on binding of serum 
fiom HIV-1-infected individuals to peptides, represent- 
ing the highly antigenic HIV-1 neutralization epitope 
of the V3 loop of known sequences from diverse iso- 
lates, have shown this method to be relevant in studying 
antigenic and genetic diversity of HIV-1 [14-161. This 
technique has also been used to provide epidemiologic 
information about the dynamics of the spread of some 
virus types in certain geographic areas [17]. 
We used this serologic approach mainly to study the 
spread of the two chimpanzee lentiviruses and one of 
the most aberrant HIV-1 strains (HIV-~ANT-~O; group 
O) in human sera fiom different geographic regions 
[18-221. We compared the antibody reactions to these 
three divergent V3 peptides with reactions to peptides 
fiom known North American and Zaïrean strains. 
Materials and methods 
Patients and sera 
A total 2495 sera plositive for HIV-1 antibodies were col- 
lected and stored at 20°C. The sera had been screened for 
HIV antibodies at the time of collection with a commer- 
cial enzyme-linked immunosorbent assay (ELISA) kit, 
and positive samples were confirmed with a commercial 
Western blot (WB) or a recombinant proteidsynthetic 
peptide line immunoassay (INNOLIA HIV-1+2, Inno- 
genetics, Ghent, Belgium). Serum samples were col- 
lected fiom symptomatic and asymptomatic individuals 
in nine different countries: Brazil (n =163, 1989-1991), 
Belgium (n =379, 1989-1992), Côte d'Ivoire (n =380, 
1990-1992), Niger (n=99, 199&1991), Cameroon 
(n=185, 1991-1992), Gabon (n=188, 1989-1992), 
Zdire (n =418,1990-1991), Kenya (n 409,1991-1992) 
and Rwanda (n=574, 1988-1990). 
Peptides 
The synthetic peptides were synthesized by Neosystems, 
Strasbourgh, France. The amino-acid sequences of the 
peptides are shown in Table 1. 
Peptide assay 
Antibodies to the V3 loop peptides were tested by 
ELISA. Stock solutions (1 mg/ml) of each peptide were 
reconstituted in 0.05 mol/l carbonate buffer (pH 9.6) 
and stored at 20°C. One hundred nanograms of peptides 
in 200 pl carbonate buffer were coated overnight at room 
temperature into each well of microtitre plates (NUNC, 
immunoplate, Copenhagen, Denmark). The plates were 
washed twice with wash solution [phosphate buffer solu- 
tion (PBS), 0.01%) merthiolate, 0.05% Tween 201 before 
use. Non-specific binding sites were blocked by incuba- 
tion with 200pl PBS containing 0.05% Tween 20 and 
2% bovine serum albumin (BSA) at 37°C for 2 h. Serum 
dilutions (1/200) were made in blocking buffer and 
200 p1 was incubated with the immobilized peptides for 
1 h at 37°C. After washing, antihuman immunoglobulin 
G peroxidase conjugate in blocking buffer was added and 
incubated for 1 h at 37°C. After washing, bound anti- 
bodies were visualized by adding substrate [8.7mg te- 
tramethylbenzidine/ml dimethylsulphoxide (DMSO) di- 
luted 1/100 in 0.1 mol/l citrate phosphate buffer, pH 
4.3 and 0.006%) H20.1. The reaction was stopped by 
adding 50 pl sulphuric acid and the optical densities 
(OD) were read a t  450nm. Ten negative sera from the 
corresponding country were used to establish the cut-off 
value of each assay, which was the mean of the OD of the 
negative sera plus three SD. Cutoff values calculated in 
this manner ranged &om 0.15 to 0.5. For uniformity and 
to eliminate non-specific reactivity the highest cut-off 
value (0.5) was used for all the assays [15,22]. 
Western blot (WB) 
WB were prepared from the H I V - ~ A N T - ~ ~  and the 
sIv,p,-,b viruses as described previously [21]. 
Table 1. Amino-acid seauences of V3 oeDtides. 
Peptides Subtype -s. Amino-acid sequences 
HIV-1 
MN 
SF2 
HXB2 
RF 
MAL 
ELI 
26 
ANT-70 
SIVcpz 
gab 
ant 
6 C N K R K R I H I C P G R A F Y T T K N  
B . . T . . S . Y  . . . . . . .  H . . C R  
B . . T . . S . T L . R .  . V I . A . G Q  
D . . T . R G .  . F . .  . Q . L . .  . C I  
D . . T . Q . T P . . L . Q S L . .  . R S R S  
D . . T . Q S T P . . L . Q . L . .  . R G T K  
O . D I Q E M R . . . M A N Y S M C I C C T A G N S  
B . . T . . Q R Q R  . . . . . .  V . I C K  
O . . T . G E V Q  . . . .  M T . . N I E . V V G D  
O 1 R T C R N L N . .  . .  M T . .  N V Q  I A T C D  
* >  .(' 
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Results 
prevalences of antibodies to the different peptides 
The prevalences of antibody reaction to different V3 
peptides in the different countries are summarized in 
Table 2. In each country the highest antibody reaction 
was observed against the HIV-1 MN peptide (subtype 
B), although prevalences were different and ranged from 
91.7 to 58.8%, with the lowest prevalence in Brazil. The 
second most recognised peptide was SF2, also belonging 
to subtype B. Antibody binding to the two other pep- 
tides from the same B subtype (HXE32 and RF) were low 
overall in all countries. 
Prevalence rates of antibodies to the peptides derived 
fiom Zairean strains belonging to subtype D were gener- 
ally lower. Antibodies to this subtype were almost absent 
in sera from Brazil, and the OD were low (OD < 1.5 or 
OD/cut-off ratio < 3). 
Relative high prevalences were seen for the V3 loop 
peptides derived from the chimpanzee lentiviruses, espe- 
cially for the peptide from the SIVcpz-gb strain, isolated 
from a chimpanzee in Gabon. The lowest rates were 
seen in Brazil (4.2%) and Belgium (25.7%). Among the 
Afiican countries, the highest prevalences were observed 
in West Africa and the lowest in the East Afiican coun- 
try of Kenya (Table 2). Prevalences to the V3 loop de- 
rived from the SIVcpz-a,lt strain were much lower. Most 
of the sera (YlN) reacting with the SIVcp,-ant peptide 
reacted simultaneously with the sIv,-p,-,b peptide; the 
remainder (9%) had only weak antibody reactions to the 
SIVcpane peptide. 
Prevalences of sera reactive to the V3 loop peptide 
derived &om the aberrant strain HIV~ANTJO, from 
Cameroon, were very low. The highest rates were ob- 
served in Cameroon (10.2%). Nieer (6%) and Gabon 
Simultaneous antibody response to various 
peptides and to different subtypes 
As can be seen from the data on the prevalences to each 
individual peptide (Table 2), the majority of the sera 
reacted with more than one peptide. The amount of sera 
reacting simultaneously with different peptides varies for 
each country (data not shown). 
Among the 2495 sera tested, 2439 were analysed further 
for the possible combinations of antibody patterns to the 
three major subtypes (subtypes B and D, and SIVcPz). 
Sera reactive with one or more V3 peptides of HIV-1 
isolates from subtype B were observed most frequently 
(31.8%). 
Overall, 1007 sera (41.394) had antibodies to the pep- 
tides &om subtype D, among which 22 reacted only with 
these peptides. AU others also showed a reaction to one 
or more peptides from subtype B. 
Of all the sera tested, Y05 (37.1%) out of 2439 reacted 
with at least one of the two SIV,,, peptides. Among 
these, 319 (35.2%) reacted simultaneously with subtype 
B peptides, only 23 (2.5%) with subtype D and 524 
(57.Y%) with both. Thirty-nine sera reacted only with 
SIV,,, peptides. 
Antibody reaction to HIV-lANT-,O peptide in 
combination with other genetic subtypes 
On the 2495 sera tested, 81 (3.2%) had antibodies to 
the H 1 v - 1 ~ ~ ~ 7 0  peptide. We subdivided these sera into 
three groups according to OD and examined the number 
of simultaneous reactions with other peptides. The ma- 
jority of the sera (61 out of 81) reacting with ANT-70 
had low antibody reactions (OD < 1.5); only six (YS%) 
of these reacted with the HIV-~ANT-~O peptide only 
or in combination with one subtype only, versus five 
(55.5%) out of nine, and nine (81.8%)) out of 11 in 
the groups with intermediate (1.5 < OD < 2.5) and high 
(OD > 2.5) antibody response, respectively. A high OD 
with the HIV-~ANT-~O peptide indicates a more specific 
reaction. 
- (4.6%). Reactions witd high ÖD (52.5) were only seen 
in Cameroon and Gabon, two neighbouring countries, 
where reactions were very specific to this peptide. 
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Relation between antibody response to 
HIV-1 A N T J ~  and SIVcpz-gab peptides and gpl20 
antibodies on WB 
Thirty-six sera with antibodies to the H I V - ~ A N T - ~ ~  
peptide and eight sera with antibodies to the SIv,-,,&, 
peptide only were tested on in-house WB strips from 
the corresponding viruses. The sera were subdivided in 
different categories according to their OD. All eight sera 
with OD > 2.5 had antibodies to the whole gp120 of the 
H 1 v - 1 ~ ~ ~ ~ 7 0  virus on WB, versus three out of six sera 
with OD be.tween 1.5 and 2.49, and three out of 16 sera 
with OD between 0.5 and 1.49. These three sera had 
antibodies to H I V - ~ A N T - ~ ~  peptide ody. None of the 
six sera without antibodies to the H I V - ~ A N T - ~ ~  peptide 
reacted with the gp120 (Table 3). 
One of the eight sera with antibodies to the SIVcpz-$, 
peptide only and with OD > 2.5 showed a weak antibody 
reaction to the a 1 2 0  protein of the corresponding virus 
on WB. I 
! 
subtype B were generally lower as observed in previous 
studies [14,23]. 
Prevalences of antibodies to V3 peptides derived from 
Zaïrean strains belonging to subtype D were generally 
lower than to subtype B. The highest reactivities were 
observed in sera &om Africa, although no significant dif- 
ferences were observed between East, Central and West 
African countries. Interestingly, antibodies to these pep- 
tides are almost always associated with antibodies to sub- 
Surprisingly, high amounts of sera had antibodies to the 
peptides derived from the chimpanzee lentiviruses, es- 
pecially to the sIV,p,-,b v3 peptide. In analogy to 
the subtype D peptides very low reactions were seen in 
Brazil. For the Belgian sera a link with Africa or Afi-icans 
was documented (data not shown), also indicating that 
these are peptides with an African origin. This was also 
the case for reaction with subtype D peptides in Belgian 
sera. 
Onlv 3% of sera reacted with the H I V - ~ A N T - ~ ~  pep- 
type B. 
Table 3. Number of sera with antibodies to gpl20 outer membrane tide, among which only a small Percentage reacted to 
protein of HIV-~ANTJ~  according to optical densities (OD) of reac- the HIV-~ANTJO peptide only. This peptide seemed 
tions to the ANT70 V 3  peptide in enzyme-linked immunosorbent to be more specific than the others tested, especially 
assay (ELISA) in the different countries. when high OD were observed. From our results, this 
virus seemed to be located in two neighbouring Central OD to ANT-70 
A f i i c a n  countries, Gabon and Cameroon, and confirms 
in ELISA tested Western blot data of a previous preliminary study [36]. In support of 
our findings, a new HIV-1~~~-70-l ike virus (MVP51SO) 
, OD22.5 has been recently isolated from a Cameroonian HIV- 
Cameroon 7 7 positive patient [27]. For two sera reactive with the HIV- 
I t  Total 8 8 sequenced a 280 base-pair fragment in the pol region of 
i 
Gabon 2 2 that these viruses cluster with H l v - 1 ~ ~ T - 7 0  and HIV- 
Rwanda 1 O 1MV1'5180 [281* 
Zaïre 1 O 
Total 6 3 Overall, about 10% of the HIV-antibody-positive sera 
tested had no antibodies to any öf the 10 V3 peptides, 
Cameroon 6 O giving an indication that these individuals were probably 
Gabon 3 O infected with different HIV-1 strains. This is suggested 
by different studies from Brazil where V3 sequences from Rwanda 1 O 
Brazilian strains are often different from those observed Niger 3 O O 
in the US [29-311. High prevalences of sera non-reactive 
Zaïre 1 
Belgium 2 O 
Total 16 3 with any of the V3 peptides studied are not sufficient 
O alone to indicate presence of aberrant or divergent HIV- 
1 strains in a certain region. In Cameroon for example, 
where only 5.4% of the tested sera were negative (data 
not shown), we observed the highest prevalences of re- I 
1 Discussion activities with the very aberrant HIV-1 ANT-70 peptide. 
In conclusion, peptide serology using V3 peptides of 
I 
l 
I 
! 
No. positive with 
v3 peptides No. ANT-70 gpl20 in 
1 
Gabon 1 1 1ANT-70 peptide and a 1 2 0  On HIV-lANT-70 WB, We 
1.5sOD<2.5 
I Cameroon 2 1 the corresponding virus. Phylogenetic analysis showed 
0.5 SOD< 1.5 
6 
- 4 -  
O D  <0.5 
I 
I In each the highest prevalences were observed HIV-1 isolates belonging to different subtypes helps to 
against the HIV-lMN peptide, to subwe B. 
The prevalence of 88*8% in Belgian Sera is comparable 
rapidly document the existence of different V3 pep- 
tide reactivity patterns in different geographical localities. 
with the 79-1000/;; observed in the United States and 
As described previously for East Afiican countries 
[14,25], our study showed that in West and Central 
African countries the prevalences to the H 1 v - l ~ ~  pep- 
tide were high. Seroreactivity to other peptides from 
The extent to which these patterns reflect the circula- 
tion of different HIV-1 strains in a particular popula- 
tion is not yet clear due to the simultaneous reactions 
with peptides from different strains and subtypes. The 
relevance of human sera containing antibodies reactive 
to the SIV,,, peptides in ELISA needs to be fùrther 
I Europe [14,23-251. 
1 
1 
I 
I 
ì 
l 
l 
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clarified by sequence data. The large number of sera that 
reacted simultaneously with other peptides indicate that 
these are more likely to be crossreactions than specific 
antibody responses. On the other hand, reactions with 
the HIV-lANT-70 peptide are more specific and serology 
using the v3 peptide of HIV-~ANT-~O can increase the 
chance of finding viruses belonging to subtype O in a 
particular population. 
Studying the spread of HIV-1 viruses fiom group O is 
important since some of their sera react negatively in 
Some HIV-screening assays and produce indeterminate 
WEi patterns [32]. Studying the spread of these viruses 
will give an indication as to whether the present guide- 
lines and strategies for .blood screening and serodiagnosis 
need modification. 
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